There are lessons to be learned from venoms.
Understanding how this works has potential for therapeutic purposes.
Joseph Papa shed light on the potential strategy for reducing the drug maker's debt load.
Combination approaches have the potential to generate twice as many sales in the recurrent RCC market.
For the first time scientists have identified a molecule that promotes the progression of the disease which affects 6,500 people in the UK.
An early review conducted by The Food and Drug Administration (FDA) of Sanofi’s combination diabetes drug iGlarLixi is raising issues related to efficacy.
Janssen Phase 3 data presented for the first time at Digestive Disease Week 2016 showed that a significantly greater proportion of adult patients with moderate to severe Crohn's disease receiving Stelara (ustekinumab) subcutaneous (SC) maintenance therapy were in clinical remission at one year.
New results from a Phase 1 clinical trial that tested Eli Lilly’s investigational CDK4/6 inhibitor indicates that abemaciclib is likely in line to become an FDA-approved CDK4/6 inhibitor.
The recent legalization of cannabis for medical purposes in some US states has reinvigorated the debate over cannabis in Germany.
A drug for breast cancer that is more effective than existing medicines may be a step closer thanks to new research.
The spread of yellow fever is a global health threat.
“Cure” is a word that’s dominated the rhetoric in the war on cancer for decades.
Analyses remain ongoing and will be the subject of future publications and presentations.
All three firms aim to contribute to the enhancement of health and welfare of people around the world through creating innovative medicine.